Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes

Pancreatic cancer is the seventh leading cause of cancer-related mortality in both sexes across the globe. It is associated with extremely poor prognosis and remains a critical burden worldwide due to its low survival rates. Histologically, pancreatic ductal adenocarcinoma (PDAC) accounts for 80% of...

Descripción completa

Detalles Bibliográficos
Autores principales: Akhuba, Liia, Tigai, Zhanna, Shek, Dmitrii
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775646/
https://www.ncbi.nlm.nih.gov/pubmed/36551952
http://dx.doi.org/10.3390/biomedicines10123196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775646/
https://www.ncbi.nlm.nih.gov/pubmed/36551952
http://dx.doi.org/10.3390/biomedicines10123196

Ejemplares similares